1. Antisense therapy targeting complement factor B. (October 2018) Authors: Grossman, Tamar; Carrer, Michele; Johnson, Robert; Shen, Lijiang; Hettrick, Lisa; Henry, Scott; Monia, Brett; McCaleb, Michael Journal: Molecular immunology Issue: Volume 102(2018:Oct.) Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pharmacodynamic efficacy of IONIS-FB-LRX, a complement factor B antisense oligonucleotide, in a phase 1 clinical study. (October 2018) Authors: McCaleb, Michael; Hughes, Steve; Greary, Richard; Monia, Brett; Grossman, Tamar Journal: Molecular immunology Issue: Volume 102(2018:Oct.) Page Start: 187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses. Issue 10 (16th August 2022) Authors: Han, Kelong; Theodore, Dickens; McMullen, Gina; Swayze, Eric; McCaleb, Michael; Billioud, Gaetan; Wieland, Stefan; Hood, Steve; Paff, Melanie; Bennett, C. Frank; Kwoh, T. Jesse Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 10(2022) Page Start: 1191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗